Navigation Links
AMP comments at FDA meeting on array-based tests
Date:6/30/2010

Bethesda, MD (June 30, 2010): Today, the Association for Molecular Pathology (AMP) presented comments at the US Food & Drug Administration's public meeting on array-based cytogenetic tests. The FDA convened the meeting to seek answers to more than a dozen questions they had on how to evaluate the performance, interpret results and report findings of array-based cytogenetic tests for copy number variation (CNV).

AMP believes array-based cytogenetic tests provide much higher resolution than traditional karyotyping, with expansive capabilities to diagnose and identify causes of genetic syndromes due to chromosome abnormalities. The standard of care in molecular and cytogenetic laboratories as well as genetics clinics is shifting from traditional karyotyping to array-based cytogenomic analysis. "This new technology has provided diagnoses that would have otherwise not been possible with older methods," explained Dr. Mark Sobel, AMP Executive Director.

Professional societies, such as AMP, are currently working to develop professional practice guidelines to address many of the questions raised by the FDA that focus on interpreting and reporting results of array-based cytogenetic tests. AMP believes that the interpretation of these tests falls within the scope of professional practice and that while the FDA should evaluate the technology platform for analytical validity, the FDA does not need to review each possible CNV result. "It is important to remember that all testing is performed in the context of the phenotype of the patient, and interpretation of laboratory data is a collaboration between the clinical scientist and the treating physician," said Dr. Sobel. AMP encourages the FDA to partner with professional associations to collaborate on the best manner to standardize the use and reporting of array-based tests.

AMP believes that to advance the use of array-based cytogenetic tests, the molecular cytogenetic field needs to collect data on both the laboratory results and clinical information. Dr. Sobel added, "Such a database will enable the community to continually assess the validity of results and accelerate the understanding of the results." AMP encourages the government to fund clinical research to further explore the associations between array findings and health information.


'/>"/>

Contact: Mary Steele Williams
mwilliams@amp.org
301-634-7921
Association for Molecular Pathology
Source:Eurekalert

Related biology news :

1. AVAC comments on NIAID decision not to move forward with PAVE 100 Trial
2. Director of Berman Institute comments on FDA Approval of first human embryonic stem cell trial
3. AMP submits comments on SACGHS report
4. Society for General Microbiology 161st Meeting, University of Edinburgh
5. Planetary geoscience, paleontology, and more at GSA Annual Meeting in Denver next month
6. Colony collapse disorder symposium added to ESA Annual Meeting
7. Meeting real-world climate information needs of business, government
8. Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings
9. NAS Biodiversity and Extinction Meeting Dec. 7-8
10. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
11. New studies on schizophrenia, depression, trauma and autism highlight annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... NEW YORK , March 2, 2017 Summary ... to better understand Perrigo and its partnering interests and activities ... ... The Partnering Deals and Alliance since 2010 report provides an ... world,s leading life sciences companies. On demand company ...
(Date:3/1/2017)... Mass. , March 1, 2017  Aware, Inc. ... services, announced that Richard P. Moberg has ... and co-President and Chief Financial Officer and Treasurer of ... continue to serve as a member of the Board ... Russell , Aware,s co-Chief Executive Officer and co-President, General ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... ... , ... Okyanos Cell Therapy has announced Tallahassee, FL will be the next ... Cell Therapy: The Next Phase in the Evolution of Medicine.” As the Bahamas’ first ... Therapy Act, Okyanos maintains a mission to help “no-option” patients and those with ...
(Date:3/22/2017)... Diego, Calif. (PRWEB) , ... March 21, 2017 ... ... on Kickstarter , more than tripling its goal and raising over $30,000 ... low-maintenance vertical garden that grows nutritious veggies & herbs fast, easy, and affordably, ...
(Date:3/22/2017)... CARDIFF, UK (PRWEB) , ... March 21, 2017 , ... ... and tissue oxygenation, is being explored as a way to track the brain’s response ... on tonic pain activation by cold pressor test ,” published today in the ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel , March ... a leading developer of adult stem cell technologies for ... Chief Executive Officer, will provide an update on new ... nd Annual Neuroscience Biopartnering and Investment Forum, being ... York Academy of Sciences. ...
Breaking Biology Technology: